Developing mRNA vaccines to stimulate immune responses against HIV
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs
['FUNDING_OTHER'] · FRED HUTCHINSON CANCER CENTER · NIH-11092358
This study is testing new mRNA vaccines designed to boost the immune system's ability to fight HIV by focusing on specific parts of the immune cells that make antibodies, and it's aimed at helping people who are looking for better ways to protect themselves against the virus.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11092358 on ClinicalTrials.gov |
What this research studies
This research focuses on creating self-amplifying mRNA vaccines that aim to enhance the immune response against HIV by targeting specific B cell receptors. The approach involves using two different immunogens designed to activate and mature these receptors, which are crucial for producing effective antibodies against the virus. Initially, the study will compare the immune responses generated by these mRNA vaccines with those produced by traditional protein-based vaccines in preclinical models. If successful, the mRNA vaccines will be manufactured for clinical trials in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at risk of HIV infection or those who are HIV-positive and seeking innovative treatment options.
Not a fit: Patients who are not at risk for HIV or those who are already receiving effective treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines against HIV, potentially improving prevention and treatment options for patients.
How similar studies have performed: Previous research has shown promise in using mRNA technology for vaccine development, indicating potential success for this novel approach.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STAMATATOS, LEONIDAS — FRED HUTCHINSON CANCER CENTER
- Study coordinator: STAMATATOS, LEONIDAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.